[Objective]To investigate the clinical effect of levonorgestrel-releasing intrauterine system(mirena) in the treatment of adenomyosis. [Methods]60 patients with adenomyosis were randomly divided into two groups:30 patients received operation, the other 30 patients took mirena, all patients followed up for endocrine, sexual life, pelvic pain after treatment, and follow up for the dysmenorrhea, menstrual amount,menstrual period, blood CA125 after treatment of mirena. [Result] (1)After operation, the Blood FSH is higher than before, but no difference in the treatment of miream,also, it is higher in the patients treated with operation than the other; (2) The sexual life and pelvic pain are better in the patients taking the mirena than the other;(3) The dysmenorrhea, menstrual amount, menstrual period, blood CA125 are all improved after taking mirena. [Conclusion]Treatment of mirena for the patients of adenomyosis has high clinical significance, it should be popularizing.%[目的]探讨左炔诺孕酮宫内缓释系统(LNG-IUS;商品名:曼月乐)在治疗子宫腺肌病中的临床疗效.[方法]将60例在我院确诊并有手术指征的子宫腺肌病患者随机分成两组,手术组和放置曼月乐组,每组30例.比较两组治疗后内分泌、性生活、盆腔疼痛的改变,曼月乐组治疗前后在痛经程度,经量,经期及血清CA125等临床指标的变化.[结果](1)手术组在手术后6个月测定的FSH值较手术前明显升高,差异呈显著性(P＜0.01),放置曼月乐组在放置后6个月测定的FSH值与放置前比较均无统计学差异(P＞0.05).手术组6个月后测定的FSH明显高于曼月乐组,差异呈显著性(P＜0.01);(2)曼月乐组放置后6个月性生活质量明显优于手术组,盆腔疼痛症状明显小于手术组,差异呈显著性(P＜0.01);(3)放置曼月乐后痛经症状明显缓解,经量明显减少,经期缩短,血清CA125降低,差异有统计学意义(P＜0.01).[结论]曼月乐治疗子宫腺肌病切实有效,值得临床推广.
展开▼
